Breast Implant Illness: Understanding Symptoms, Evidence and Assessment

Breast implant illness, often shortened to BII, describes systemic symptoms that people report in connection with breast implants. Systemic means affecting the body beyond the breast or implant area. These symptoms deserve careful attention, but BII does not currently have an agreed diagnostic test or a universally accepted definition. Assessment should consider both implant-related problems and other possible causes. Some people report improvement after implant removal, but neither improvement nor its extent can be reliably promised.

1. What Does Breast Implant Illness Mean?

The US Food and Drug Administration describes BII as a term used by patients and clinicians, rather than a formal medical diagnosis with established criteria. This distinction concerns how an illness is defined and investigated, not whether someone is experiencing symptoms.

Three kinds of information are often discussed together: a person's symptoms, a report submitted to a safety regulator, and a diagnosed medical condition. They are related, but they are not interchangeable.

A useful consultation keeps these distinctions clear without making the patient defend the reality of their symptoms. It should be possible to take someone's experience seriously while remaining uncertain about its explanation.

2. Which Symptoms Have People Reported?

Symptoms described in FDA reports include fatigue, difficulty remembering or concentrating, joint and muscle pain, hair loss, weight changes, anxiety and depression. People also report symptoms such as rashes, headaches, sleep disturbance and digestive problems. The informal expression brain fog generally refers to difficulties with concentration, memory or mental clarity.

Regulators have received reports involving saline-filled and silicone-filled implants, including different surface types. Symptoms have been reported soon after implantation and years later. This does not establish that every implant type carries the same risk, or that the timing proves a connection.

These symptoms can substantially affect well-being. Health Canada also emphasizes that they can have many explanations unrelated to implants. A symptom checklist therefore cannot diagnose BII, identify a mechanism or tell someone whether removal will help.

Rather than counting how many symptoms match an online list, consider preparing a short account of what has changed. Which symptoms interfere most with work, sleep, relationships or everyday activities? What would meaningful improvement look like? Those details make the discussion more useful than a simple yes-or-no label.

3. What Can Safety Reports and Research Show?

3.1 Safety Reports Identify Concerns, Not Incidence

The FDA's medical device reporting system is a passive surveillance system: it receives reports rather than systematically examining every implant recipient. Such reports can help identify possible safety signals that deserve investigation.

However, the FDA explicitly warns that reports may be incomplete, duplicated, inaccurate or unverified. Some events are never reported. The system also lacks the device-use information needed to calculate how often an event occurs among implant recipients.

Consequently, report counts are not incidence figures. A percentage describing symptoms within submitted reports is not the percentage of all people with implants who experience those symptoms. Reports of improvement after removal likewise cannot provide a dependable personal probability of benefit.

3.2 Observed Improvement Does Not Prove a Mechanism

A prospective ASERF study published in 2023 followed patients forward in time, collecting symptom questionnaires before and after surgery. It included people seeking removal because of symptoms they attributed to implants, alongside two comparison groups. The symptomatic group reported improvement that persisted through the study's one-year follow-up.

That is relevant evidence, but the study was not a randomized comparison of symptomatic people assigned either to removal or to keeping their implants. Participants knew they had undergone surgery. Its comparison groups were not equivalent symptomatic patients receiving nonsurgical care. These features limit conclusions about why symptoms changed.

The study also enrolled a selected population undergoing elective aesthetic breast surgery. Its findings cannot automatically predict outcomes for every implant recipient, including people whose circumstances differ substantially. Improvement in a group is not proof of a single biological explanation or a guarantee for an individual.

Two questions therefore need separate answers: did participants feel better after removal, and did the research establish why? Evidence supporting the first does not necessarily settle the second.

4. How Should Symptoms Be Assessed?

A practical clinical approach begins with listening, a medical history and assessment of the symptoms. Depending on the findings, clinicians may recommend laboratory testing or referral to another specialist. The purpose is to look for treatable explanations, not simply to accept or reject an implant-related label.

Primary care and a clinician experienced in breast implant assessment can have complementary roles. One discussion can address broader health concerns while another examines the breasts, implant history and possible local complications. Individual clinical advice is important because the appropriate evaluation depends on the symptoms, examination and medical background.

4.1 Prepare a Clear History

Consider bringing the following information to an appointment:

• Your implant card or available records, including previous implant operations.
• A timeline showing when symptoms began and how they have changed.
• A list of current medicines, supplements and known medical conditions.
• Previous test results, imaging reports and specialist assessments.
• A short description of the symptoms that most affect your daily functioning.

If records are missing, say so rather than delaying the conversation until everything is available. You can also ask the clinician to explain which missing details would actually change the assessment.

4.2 Keep the Evaluation Open to Other Explanations

Investigating other causes is not the same as deciding implants are irrelevant. It helps avoid overlooking an illness that needs its own treatment. Conversely, an assessment that has not yet found an explanation does not automatically establish that implants are responsible.

Ask what each proposed test is intended to investigate and how its result would change care. Because there is no specific diagnostic test for BII, the evaluation should not be presented as a blood test that definitively confirms or excludes it.

Before leaving, request a clear follow-up plan: who will review the results, what remains uncertain, and what happens if symptoms continue. You do not need to settle every question about removal at the first appointment.

5. Does Implant Removal Improve Systemic Symptoms?

Explantation means surgical removal of an implant. Regulators acknowledge that some people report improvement after explantation, while the relationship between implants and systemic symptoms remains uncertain. The decision is therefore not a choice between a guaranteed cure and doing nothing.

Options for discussion include further assessment, treatment of identified conditions, symptom-focused care and implant removal. These conversations can occur together. Looking for other explanations need not prevent someone from asking about surgery, and choosing surgery should not end appropriate medical follow-up.

Removal also has risks. The FDA highlights surgical and anesthesia risks, potential bleeding or tissue injury with more extensive dissection, and changes in breast appearance after removal without replacement. Those considerations should be weighed against the person's concerns, preferences and any separately identified implant complication.

A useful decision discussion makes room for several outcomes: substantial improvement, partial improvement or persistent symptoms. Ask how ongoing symptoms would be investigated and managed rather than assuming that surgery would close the case.

5.1 More Capsule Removal Is Not a Proven Guarantee

The capsule is the scar tissue that forms around an implant. Capsulectomy means removing some or all of that tissue. Implant removal and capsule removal are separate decisions.

The ASERF study did not find significantly different systemic symptom improvement between the capsulectomy types studied. That finding does not prove that one surgical approach is appropriate for everyone. It does challenge promises that a particular extent of capsule removal guarantees improvement.

The Breast Surgery Collaborative Community's June 2024 consensus defines en bloc capsulectomy as removal of the capsule with a margin of uninvolved tissue for suspected or established implant-associated cancer after appropriate investigation. It is not simply another name for removing an intact capsule, and the consensus does not identify systemic symptoms alone as its indication.

Ask the surgeon to describe the proposed operation in plain language, explain the reason for capsule removal, and distinguish any established medical indication from an uncertain hope of systemic symptom improvement.

6. Breast Changes Need Their Own Assessment

Breast implant illness should not become a catch-all explanation for changes around an implant. Persistent breast swelling, pain or other new local changes warrant clinical evaluation. Established complications include rupture and capsular contracture, which is tightening of the scar capsule around an implant.

Breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, is a distinct cancer diagnosis, not another name for BII. The FDA advises assessment of persistent swelling, pain or changes around an implant because examination, imaging or testing of surrounding fluid or tissue may be needed. A confirmed diagnosis can change the operation required.

Do not wait for a routine discussion about systemic symptoms before reporting a new breast change. Ask the treating team how quickly it needs assessment.

7. Questions That Support an Informed Consultation

You can use these questions to keep the conversation focused:

• What possible explanations are you considering for my symptoms?
• Is there evidence of a local implant complication?
• Which tests or referrals would help, and what would they change?
• What are my options if I prefer not to have surgery now?
• If I choose removal, what benefit remains uncertain?
• Are you recommending capsule removal, and for what specific reason?
• What are the additional risks of the proposed surgical approach?
• How will we assess and support me if symptoms persist?

The central message is that uncertainty should lead to careful assessment, not dismissal or promises. Symptoms deserve attention, safety reports deserve investigation, and removal deserves a balanced discussion. None of those steps requires claiming that current evidence can prove the cause or predict the outcome for every person.